🔎 Trials Near Me

Beranda › Kanker Metastatik › Nevada › Reno

Uji klinis Kanker Metastatik di Reno, NV

5 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Reno (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Menerima pesertaFase 2
  • Renown Regional Medical Center, Reno
Semua usia · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05564377

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Menerima pesertaFase 3
  • Renown Health Medical Oncology, Reno
  • Renown Regional Medical Center, Reno
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Menerima pesertaFase 2/3
  • Renown Health Medical Oncology, Reno
  • Renown Office of Clinical Research, Reno
  • Renown Regional Medical Center, Reno
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06989437

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Menerima pesertaFase 3
  • The Center of Hope, Reno
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213804

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Menerima pesertaFase 3
  • Research Site, Reno
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07647328

Uji klinis Kanker Metastatik di kota lain

Studi lain di Reno

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.